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Background. Incomplete antiretroviral therapy (ART) adherence, even if sufficient to maintain viral suppression, is associated 
with enhanced inflammation in persons with HIV (PWH). However, its clinical implications remain unknown.
Methods. PWH enrolled in the Swiss HIV Cohort Study without a history of cardiovascular disease (CVD) who initiated ART 
between 2003 and 2018 and had viral suppression (<50 copies/mL) for ≥6 months were evaluated. The association between in-
complete self-reported ART adherence (≥1 or ≥2 missed doses in the last month) and (1) any CVD event (myocardial infarction, 
revascularization, cerebral hemorrhage, stroke, and/or death due to CVD event) or (2) non-CVD-related death was evaluated using 
adjusted Cox proportional hazards models.
Results. A total of 6971 PWH (74% male) were included in the analysis (median age [interquartile range {IQR}], 39 [32–47] 
years). The median (IQR) follow-up was 8 (4–11) years, with 14 (8–23) adherence questionnaires collected per participant. In total, 
205 (3%) participants experienced a CVD event, and 186 (3%) died a non-CVD-related death. In an adjusted competing risk model 
where missing data were imputed, missing ≥1 ART dose showed an increased, but not statistically significant, risk for CVD events 
(hazard ratio [HR], 1.23; 95% CI, 0.85–1.79; P = .28). Non-CVD-related mortality showed a statistically significantly increased risk 
with missing ≥1 ART dose (HR, 1.44; 95% CI, 1.00–2.07; P = .05) and missing ≥2 ART doses (HR, 2.21; 95% CI, 1.37–3.57; P = .001).
Conclusions. Incomplete ART adherence was significantly associated with an increased risk for non-CVD-related mortality 
in PWH with virologic suppression. This highlights the potential role of nonadherence to ART as a driver of non-AIDS clinical 
outcomes.
Keywords. adherence; antiretroviral therapy; cardiovascular disease; viral suppression.
Despite achieving suppressed viral replication by conventional 
assays, persons with HIV (PWH) taking antiretroviral therapy 
(ART) have residual systemic inflammation that has been as-
sociated with the development of serious non-AIDS events 
and increased all-cause mortality [1, 2]. While the underlying 
causes of this residual inflammation and immune activation are 
not completely understood, they are likely to be multifactorial, 
requiring a multitargeted approach to reduce the inflammation 
[3]. Recently, ART nonadherence has been evaluated as a po-
tential driver of the chronic inflammation observed in this pop-
ulation. Recent data have demonstrated that incomplete ART 
adherence is associated with increased levels of systemic in-
flammation, immune activation, and coagulopathy in virolog-
ically suppressed individuals [4–8] and that optimal adherence 
may lead to levels of inflammation similar to those observed in 
persons without HIV [9]. Several potential mechanisms to ex-
plain this association have been proposed, in particular that in-
complete adherence could result in intermittent low-level HIV 
replication (ie, below the limit of detection by clinically avail-
able assays) [10–12], resulting in enhanced inflammation and 
immune activation [13, 14]. However, despite being identified 
in several studies, the association of incomplete adherence with 
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chronic residual inflammation in PWH who are virally sup-
pressed currently lacks clinical significance.
Several—but not all—studies have demonstrated that, com-
pared with persons without HIV, PWH may be at increased 
risk of developing cardiovascular disease (CVD) [3, 15–21]. In 
particular, PWH have an increased risk of myocardial infarc-
tion (MI), which has been postulated to be driven by traditional 
cardiovascular risk factors, but also by HIV-specific risk factors 
such as type of ART, CD4+ T-cell count, and HIV viremia [16, 
22]. Chronic residual inflammation has also been postulated 
as a major contributor to the increased cardiovascular risk in 
PWH by promoting atherosclerosis [23–27]. Given its asso-
ciation with residual inflammation, immune activation, and 
coagulopathy, incomplete ART adherence could also lead to an 
increased frequency of atherosclerotic CVD, even in the setting 
of viral suppression, which was the focus of this study.
METHODS
Study Cohort and Participants
The SHCS is a prospective multicenter study cohort that follows 
~75% of all PWH on ART in Switzerland [28] and has enrolled 
participants since 1988 from within 7 outpatient HIV clinics at 
participating medical centers (Basel, Bern, Geneva, Lausanne, 
Lugano, St. Gallen, and Zurich) or from private physicians [29]. 
Study visits in the SHCS occur every 6 months and include re-
view of medical history and new diagnoses, physical examin-
ations, medication review, evaluation of ART adherence, and 
laboratory evaluations, as previously described [30].
We conducted an analysis of PWH registered in the SHCS and 
initiating ART between January 1, 2003 (introduction of ART 
adherence questionnaire), and December 31, 2018. Participants 
were required to have ≥6 months of viral suppression (HIV-1 
RNA < 50 copies/mL) and no history of CVD at baseline. Viral 
blips (HIV-1 RNA ≥50 copies/mL and <400 copies/mL fol-
lowed by an HIV-1 RNA VL <50 copies/mL) were allowed and 
included as time-dependent variables. Database closure was on 
January 31, 2020.
Outcomes
Participants were determined to have a CVD event if they de-
veloped any of the following clinical entities from within a 
composite outcome, as previously described [31–34]: myocar-
dial infarction (MI), revascularization (coronary angioplasty/
stenting, coronary artery by-pass grafting, carotid endarterec-
tomy, procedures on other arteries), cerebral hemorrhage, ce-
rebral infarction (stroke), and/or death due to cardiovascular 
disease. Framingham risk score (FRS) was calculated using a 
validated formula, as previously described [35].
ART Adherence
Adherence in the SHCS is assessed using a simplified and valid-
ated self-reported questionnaire that contains 2 questions (asked 
by the participant’s clinician), as previously described [36–38]. 
“Adherence” is assessed by the question “How often did you 
miss a dose in the last 4 weeks?” (daily, more than once a week, 
once a week, once every second week, once a month, never). 
“Drug holidays” are assessed by the question “Did you have a 
period of no drug intake for >24 hours in the last 4 weeks?” 
(yes/no) [38]. Two definitions of incomplete ART adherence 
were utilized, (a) ≥1 and (b) ≥2 missed ART doses in the last 4 
weeks, to reflect any missed doses in the last 4 weeks. These def-
initions have previously been associated with viral failure [37, 
39], mortality [39], and drug resistance [40] in this cohort. We 
selected a relatively high adherence threshold (ie, any missed 
doses) based on our previous research, where <100% adherence 
has been associated with heightened residual inflammation, im-
mune activation, and coagulopathy [4–7].
Statistical Analysis
Baseline was defined as the date the participant suppressed 
their viral load for 24 weeks. Descriptive statistics were used 
to summarize baseline characteristics and outcomes. We esti-
mated cause-specific event rates for CVD, mortality, and viral 
failure using cumulative incidences [41, 42] and assessed fac-
tors associated with cause-specific events using various Cox 
proportional hazard ratio (HR) models [41]. In addition to a 
univariate model that evaluated the association of incomplete 
adherence with CVD events, we evaluated additional models 
that assessed for competing risk from non-CVD-related death. 
This was intended to account for the possibility that a partici-
pant could have experienced this event, which might compete 
with the outcome of interest, thus hindering the observation 
or the chance that the event of interest occurred. Time at risk 
excluded periods when participants were lost to follow-up/
transferred to other clinics, at which point participants were 
censored.
To address missing baseline covariates, we used multiple im-
putation with chained equations, assuming data were missing 
at random [43]. In the imputations, we used multinomial re-
gression for FRS category; truncated regression for inverse-
square-root-transformed BMI, square-root-transformed 
cholesterol, HDL, systolic blood pressure, square-root-
transformed CD4+ T-cell count, and square-root-transformed 
log of HIV-1 RNA; and logistic regression for injecting drug 
use, smoking, Caucasian ethnicity, and family history of CVD 
(ie, history of MI or stroke before age 50 in any first-degree re-
latives). In addition to the baseline covariates, we included ad-
herence across all follow-up in the imputations, an indicator 
for outcome (CVD, death due to non-CVD-related or un-
known causes, or censored), and the Nelson-Aalen estimator 
of the baseline cumulative hazard [43, 44]. We used 10 imput-
ations, based on at least the approximate fraction of missing 
information [45]. All analyses were conducted in Stata, ver-
sion 15 (StatCorp LLC).
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Patient Consent Statement
All patients who are part of the SHCS have given their written 
consent to use their data for research purposes.
RESULTS
Study Population
A total of 7883 PWH initiated ART between 2003 and 2018. Of 
these, 912 (12%) were excluded for the following reasons: 450 
were not on ART for at least 12 months, 8 had no VL done after 
starting ART, 288 did not achieve viral suppression (n = 58) 
or were not suppressed for a minimum of 24 weeks (n = 230), 
120 had a CVD event before baseline, and 46 did not have ad-
herence information recorded during follow-up. Table 1 shows 
the demographic characteristics of the 6971 PWH included in 
the study population according to outcome. Overall, the me-
dian (interquartile range [IQR]) age was 39 (32–47) years; 5164 
(74%) of the cohort were male and 5084 (73%) were Caucasian. 
A total of 709 (11%) participants had a family history of CVD, 
2252 (37%) were overweight or obese, and 2493 (41%) were 
smokers. Diabetes was present in 150 (2%) participants, and 
450 (8%) had an FRS >20%.
ART Adherence and Clinical Outcomes
In multivariable models, missing ≥1 ART dose in the past 4 
weeks as assessed by a questionnaire was associated with an 
HR of 1.11 (95% CI, 0.76–1.61; P = .59) for CVD events in uni-
variate analysis and 1.35 (95% CI, 0.90–2.03; P = .15) in multi-
variate analysis (Table 2, Model 1a). When missing data were 
imputed, the multivariate HR was 1.23 (95% CI, 0.85–1.79; 
P = .28) (Table 2, Model 2a). Finally, our findings for the HR 
for CVD events and non-CVD-related death were comparable 
when missing ≥2 ART doses was evaluated as the predictor 
(Table 2, Models 1b and 2b).
For the outcome of non-CVD-related mortality, we found 
that missing ≥1 dose of ART was associated with an HR for 
non-CVD-related mortality of 1.46 (95% CI, 1.02–2.09; P = .04) 
in univariate analyses and 1.44 (95% CI, 1.00–2.07; P = .05) in 
multivariate analyses where missing data were imputed, respec-
tively (Table 2, Model 2a). In a model that assessed ≥2 missed 
ART doses, the HR was 2.21 (95% CI, 1.38–3.56; P = .001) in 
a univariate model and 2.21 (95% CI, 1.37–3.57; P = .001) in a 
multivariate model when missing data were imputed (Table 2, 
Model 2b).
In a sensitivity analysis that excluded the presence of viral 
blips from the model, the results remained almost identical to 
our original findings.
Factors Associated With CVD Events and Non-CVD-Related Mortality
The participant demographic and clinical factors associated 
with our outcome(s) of interest in Model 2b are presented in 
Supplementary Table 1. In addition to missing ≥2 doses of 
ART, Caucasian ethnicity, being underweight, having a positive 
family history of CVD disease, intravenous drug use as an 
HIV risk factor, and having an FRS >10% were all associated 
with a higher risk of CVD events or non-CVD-related death. 
Comparatively, being overweight, having a CD4 T-cell count 
between 350 and 499 cells/mm3, and having an HIV-1 RNA be-
tween 10 000 and 49 999 at the time of ART initiation were asso-
ciated with a lower risk of non-CVD-related death.
DISCUSSION
In this study, we aimed to evaluate the association between 
incomplete ART adherence and CVD events in a large obser-
vational cohort of PWH who were virologically suppressed to 
<50 copies/mL. Although not significant, we identified a pos-
itive association between these 2 variables, with a direction 
and magnitude that were consistent when we evaluated several 
models that considered non-CVD-related death as a competing 
risk and after imputing missing data. While not the initial goal 
of our study, we identified a significant association between 
incomplete ART adherence and an increased hazard of non-
CVD-related death in the study population. This association, 
which remained significant both in univariate and multivariate 
analyses and after imputing missing data, is of unique clinical 
importance because it identifies adherence to ART as a po-
tentially actionable risk factor that could be targeted to reduce 
mortality in PWH who maintain viral suppression. While pre-
vious studies have repeatedly demonstrated an association of in-
complete adherence with high residual inflammation in virally 
suppressed PWH [4–7], this is the first study, to our knowledge, 
to identify a non-AIDS adverse clinical outcome (non-CVD-
related death and CVD event) associated with incomplete (but 
suppressive) adherence to ART.
As has been previously proposed [4, 6, 7, 46], several potential 
mechanisms could explain our findings. These include intermit-
tent viral replication below the limit of detection in plasma [10, 
12] or tissue (ie, lymphoid and/or gut tissue) [47] where drug 
penetration is suboptimal [48], resulting in enhanced residual 
inflammation exacerbated by incomplete adherence. However, 
the clinical consequences of this residual viral replication remain 
controversial. While a recent AIDS Clinical Trials Group study 
(A5321) did not find a correlation between residual viral rep-
lication (using single-copy assays) and residual inflammation, 
this analysis focused on a highly selected cohort of participants 
who had long-standing viral suppression (median, 7 years) and 
were originally enrolled in clinical trials [49]. In comparison, 
other studies in different cohorts have identified associations 
of residual viremia and HIV-DNA with inflammation [14, 50, 
51] and with increased cardiovascular morbidity [26, 27]. Given 
the well-established association between residual inflammation 
and morbidity/mortality in HIV [24, 25], it remains plausible 
that suboptimal ART adherence could trigger episodes of re-
sidual HIV replication and heightened inflammation that result 
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(n = 6850) Total (n = 6971)
Age, median (IQR), y 49 (43–56) 46 (40–55) 39 (32–46) 39 (32–47)
 Missing 0 0 0 0
Gender     
 Male 172 (84) 137 (74) 4855 (74) 5164 (74)
 Female 33 (16) 49 (26) 1725 (26) 1807 (26)
 Missing 0 0 0 0
Caucasian     
 No 16 (8) 23 (12) 1842 (28) 1881 (27)
 Yes 189 (92) 163 (88) 4732 (72) 5084 (73)
 Missing 0 0 6 6
Basic education (9 y)     
 No 171 (83) 137 (74) 5041 (77) 5349 (77)
 Yes 34 (17) 48 (26) 1502 (23) 1584 (23)
 Missing 0 1 37 38
HIV transmission risk     
 Homosexual 95 (47) 63 (36) 3301 (52) 3459 (52)
 Heterosexual 82 (41) 65 (37) 2514 (40) 2661 (40)
 Injecting drug use 22 (11) 45 (25) 403 (6) 470 (7)
 Other 2 (1) 4 (2) 104 (2) 110 (2)
 Missing 4 9 258 271
Body mass index category     
 Underweight 7 (4) 14 (8) 185 (3) 206 (3)
 Normal weight 110 (59) 109 (64) 3338 (59) 3557 (59)
 Overweight 56 (30) 35 (20) 1653 (29) 1744 (29)
 Obese 14 (7) 13 (8) 481 (9) 508 (8)
 Missing 18 15 923 956
Family history of CV disease     
 No 166 (83) 154 (85) 5632 (90) 5952 (89)
 Yes 34 (17) 28 (15) 647 (10) 709 (11)
 Missing 5 4 301 310
Smoker     
 No 88 (46) 60 (35) 3416 (60) 3564 (59)
 Yes 103 (54) 113 (65) 2277 (40) 2493 (41)
 Missing 14 13 887 914
Systolic blood pressure, median (IQR) 128 (120–140) 126 (115–137) 124 (115–134) 124 (115–135)
 Missing 19 11 933 963
Diabetes     
 No 193 (94) 176 (95) 6452 (98) 6821 (98)
 Yes 12 (6) 10 (5) 128 (2) 150 (2)
 Missing 0 0 0 0
On hypertensive treatment     
 No 189 (92) 162 (87) 6306 (96) 6657 (95)
 Yes 16 (8) 24 (13) 274 (4) 314 (5)
 Missing 0 0 0 0
Total cholesterol, median (IQR), mg/dL 204 (174–236) 182 (148–210) 183 (159–213) 184 (159–213)
 Missing 15 7 769 791
HDL cholesterol, median (IQR), mg/dL 44 (36–54) 50 (39–62) 46 (39–57) 46 (39–57)
 Missing 16 7 782 805
Framingham risk score     
 <10% 66 (36) 97 (56) 4377 (78) 4540 (76)
 10%–20% 63 (34) 47 (27) 841 (15) 951 (16)
 >20% 54 (30) 28 (16) 368 (7) 450 (8)
 Missing 22 14 994 1030
ART regimen at ART initiation     
 Non-nucleoside reverse transcriptase inhibitors 92 (45) 65 (35) 2531 (38) 2688 (39)
 Protease inhibitors 101 (49) 104 (56) 2745 (42) 2950 (42)







(n = 6850) Total (n = 6971)
 Integrase inhibitors 8 (4) 10 (5) 1123 (17) 1141 (16)
 Other 4 (2) 7 (4) 181 (3) 192 (3)
 Missing 0 0 0 0
CD4+ T-cell count at ART initiation, median (IQR), cells/
mm3
235 (140–358) 215 (112–320) 285 (170–418) 280 (167–414)
 0–199 75 (40) 79 (46) 1730 (31) 1884 (31)
 200–349 63 (33) 58 (34) 1903 (34) 2024 (34)
 350–499 30 (16) 18 (11) 1124 (20) 1172 (19)
 ≥500 21 (11) 16 (9) 899 (16) 936 (16)
 Missing 16 15 924 955
HIV-1 RNA at ART initiation, median (IQR), copies/mL 11 (9–12) 11 (8–12) 11 (9–12) 11 (9–12)
 0–9999 56 (30) 61 (36) 1624 (29) 1741 (29)
 10 000–49 999 36 (19) 20 (12) 1409 (25) 1465 (25)
 ≥50 000 97 (51) 88 (52) 2570 (46) 2755 (46)
 Missing 16 17 977 1010
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; CV, cardiovascular; CVD, cardiovascular disease; HDL, high-density lipoprotein; IQR, interquartile range. 
in adverse non-AIDS clinical outcomes despite virologic sup-
pression in plasma.
Another explanatory mechanism behind our findings could be 
that incomplete adherence identifies a subset of patients who de-
velop intermittent viremia that is not captured between clinic visits 
[4], in particular given the antiviral potency and pharmacokinetic 
forgiveness of the new antiretrovirals and the current trends to-
ward less frequent monitoring in clinical care [52, 53]. This was 
particularly highlighted by the stronger association observed in 
PWH who missed ≥2 ART doses, suggesting that the clinical con-
sequences of incomplete ART adherence could be accentuated in 
a subgroup of patients with sustained low adherence. Whether 
incomplete ART adherence leads to intermittent viremia has also 
been a matter of constant debate, as some studies have shown a 
clear association between them [10, 11], while others have refuted 
this theory [54]. However, the potential association between lapses 
in ART adherence and adverse clinical outcomes could help re-
frame the conversation between clinicians and patients about the 
importance of aiming toward the highest possible adherence.
A third potential mechanism to explain our findings is that 
incomplete ART adherence could be a surrogate for low adher-
ence to other medications such as antihypertensives, statins, 
and/or antidiabetics, which was not assessed in our study, or 
that incomplete ART adherence could be associated with un-
measured bias inherent to a cohort study. This potential ex-
planation is clinically relevant, as it could lead to a discussion 
about adherence to non-ART medications, which has been sug-
gested to be lower when compared with ART in some studies 
[55]. While most of the focus on achieving and sustaining viral 
suppression in clinical practice is currently aimed at preventing 
progression to AIDS and/or transmission to others, the po-
tential deleterious consequences of incomplete ART adher-
ence (despite suppression) might become more relevant in the 
coming years, in particular given the accumulation of clinical 
comorbidities in an aging population of PWH.
As expected, risk factors that have been previously well es-
tablished to be associated with CVD events, such as Caucasian 
ethnicity, family history of CVD disease and a high FRS, were 
also observed in our group of PWH with virologic suppression 
[35]. This highlights the importance of identifying modifiable 
CVD risk factors in clinical care and prevention of PWH on 
suppressive ART. It also underscores the possibility that ART 
adherence may have considerable clinical relevance beyond 
virologic suppression. In particular, our identified association 
raises the question of whether improving ART adherence may 
be a modifiable target to reduce residual inflammation and 
immune activation [6] and prevent CVD outcomes and mor-
tality. Indirect evidence of this has been recently observed in a 
subanalysis performed by the Multicenter AIDS Cohort Study 
(MACS), where men with HIV who were virologically sup-
pressed (<50 copies/mL) and who reported 100% ART adher-
ence had similar concentrations of interleukin-6 (IL-6), soluble 
interleukin-6 receptor (sIL-6R), IL-1β, and interferon-γ, among 
other biomarkers, when compared with men without HIV, sug-
gesting that sustained and high ART adherence could lead to 
normalization of these biomarkers [9] and translate into clinical 
benefit. This hypothesis is especially supported by the normal-
ization of IL-6 given the strong association of this inflamma-
tory cytokine with CVD events and mortality in PWH [24, 56]. 
As we have limited effective strategies to reduce inflammation 
in treated HIV disease, future studies that evaluate whether an 
intervention aimed at improving ART adherence beyond sup-
pression could reduce residual inflammation and prevent CVD 
outcomes and non-CVD-related death are required.
Our study has several strengths. First, we evaluated a very 
large and well-characterized clinical “real-world” cohort rather 
Table 1.  Continued
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than a clinical trial cohort, which provides generalizability to our 
findings. However, our cohort was not racially diverse, as only 
26% of our population was non-Caucasian, which could limit 
the interpretation of our findings to resource-limited settings 
where HIV is highly prevalent. Second, compared with previous 
studies evaluating ART adherence and inflammation [4–6], our 
study encompassed a long follow-up period (2003–2020) that 
included both the pre– and post–integrase inhibitor eras. Third, 
adjudication of CVD (and other) events in the SHCS occurs cen-
trally within the Data collection on Adverse events of Anti-HIV 
Drugs (D:A:D) study, which supports consistency in our study 
outcomes [57]. Lastly, although the association of incomplete 
ART adherence with CVD events was not significant, the direc-
tion and consistency of our results across models that considered 
both competing events and multiple imputation for missing data 
support the strength of our conclusions. The lack of statistical sig-
nificance was likely due to the relatively low frequency of events 
observed in our cohort in the observed study period. Thus, fu-
ture studies utilizing more sensitive adherence measures (eg, 
objective or pharmacologic measures) where a larger number 
of CVD events are observed could lead to stronger and more 
significant associations. Among the weaknesses of our study 
were that non-CVD-related death is a heterogeneous category 
that will need to be refined in future studies assessing the asso-
ciation between ART adherence and mortality and that we only 
focused on atherosclerotic CVD (ie, we excluded heart failure). 
Furthermore, we evaluated ART adherence based on self-report, 
which can overestimate adherence [53]. This could have resulted 
in misclassification of some participants as adherent when they 
really were not and in an attenuation of the observed associ-
ations. Future studies utilizing objective pharmacologic meas-
ures—such as real-time monitoring or pharmacologic measures 
in diverse clinical cohorts—are needed.
In conclusion, our study demonstrated that incomplete (ie, 
<100%) ART adherence is associated with an increased risk for 
non-CVD-related mortality in PWH who are virologically sup-
pressed to <50 copies/mL. These findings suggest the potential 
critical role that ART adherence could have in improving clin-
ical outcomes and open the door for further research on the role 
that increasing adherence—beyond suppression—could have 
in preventing morbidity/mortality in PWH who are considered 
optimally treated. Future studies to confirm this association and 
to understand its clinical implications are needed.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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Incomplete ART adherencec     
 Missed ≥1 dose of ART in the last 4 wk
Model 1a: only considering CVD-related events 205/163    
  Univariate, n = 6971 1.11 (0.76–1.61) 0.59   
  Multivariate, n = 4750 1.35 (0.90–2.03) 0.15   
Model 2a: Competing risk models with non-CVD-related 
death as a competing event with missing data imputed
205/205  186/186  
  Univariate, n = 6971 1.11 (0.76–1.61) 0.59 1.46 (1.02–2.09) .04
  Multivariate, n = 6971 1.23 (0.85–1.79) 0.28 1.44 (1.00–2.07) .05
Incomplete ART adherencec     
 Missed ≥2 doses of ART in the last 4 wk
Model 1b: only considering CVD-related events 205/163    
  Univariate, n = 6971 1.08 (0.59–1.99) 0.80   
  Multivariate, n = 4750 1.32 (0.67–2.61) 0.42   
Model 2b: Competing risk models with non-CVD-related 
death as a competing event with missing data imputed
205/205  186/186  
  Univariate, n = 6971 1.08 (0.59–1.99) 0.78 2.21 (1.38–3.56) .001
  Multivariate, n = 6971 1.25 (0.68–2.31) 0.48 2.21 (1.37–3.57) .001
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio. 
aCVD events include myocardial infarction, revascularization, cerebral hemorrhage, stroke, and/or death due to cardiovascular event. 
bAll reported deaths except those determined to be due to CVD. 
cResults give the HR and 95% CI; competing risk models give the cause-specific HR; adjusted models include gender, Caucasian ethnicity, injecting drug use, BMI, family history of CVD, 
Framingham risk score category, CD4+ T-cell count at ART initiation, HIV-1 RNA at ART initiation, first ART regimen class, and HIV-1 viral blips (single HIV-1 RNA >400 copies/mL followed 
by HIV-1 RNA <50 copies/mL).
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